JP2025503910A5 - - Google Patents

Info

Publication number
JP2025503910A5
JP2025503910A5 JP2024543337A JP2024543337A JP2025503910A5 JP 2025503910 A5 JP2025503910 A5 JP 2025503910A5 JP 2024543337 A JP2024543337 A JP 2024543337A JP 2024543337 A JP2024543337 A JP 2024543337A JP 2025503910 A5 JP2025503910 A5 JP 2025503910A5
Authority
JP
Japan
Prior art keywords
composition
disease
combination according
disorder
cns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024543337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503910A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/011746 external-priority patent/WO2023147058A2/en
Publication of JP2025503910A publication Critical patent/JP2025503910A/ja
Publication of JP2025503910A5 publication Critical patent/JP2025503910A5/ja
Pending legal-status Critical Current

Links

JP2024543337A 2022-01-27 2023-01-27 神経疾患を処置するための組成物 Pending JP2025503910A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263303673P 2022-01-27 2022-01-27
US63/303,673 2022-01-27
US202263321335P 2022-03-18 2022-03-18
US63/321,335 2022-03-18
PCT/US2023/011746 WO2023147058A2 (en) 2022-01-27 2023-01-27 Compositions for treating neurological disease

Publications (2)

Publication Number Publication Date
JP2025503910A JP2025503910A (ja) 2025-02-06
JP2025503910A5 true JP2025503910A5 (cg-RX-API-DMAC7.html) 2026-01-19

Family

ID=87472585

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024543337A Pending JP2025503910A (ja) 2022-01-27 2023-01-27 神経疾患を処置するための組成物

Country Status (7)

Country Link
US (1) US20250109398A1 (cg-RX-API-DMAC7.html)
EP (1) EP4469156A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025503910A (cg-RX-API-DMAC7.html)
CN (1) CN119677545A (cg-RX-API-DMAC7.html)
AU (1) AU2023211606A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248890A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023147058A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118599984B (zh) * 2024-04-22 2025-12-09 暨南大学附属第一医院(广州华侨医院) Chchd2在制备促进神经干细胞增殖与分化产品中的应用
CN121878231B (zh) * 2026-03-23 2026-06-19 上海交通大学医学院附属仁济医院 分子靶点Ptchd1在神经突触功能及意识调控和相关疾病中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015370903B2 (en) * 2014-12-24 2021-06-17 Uniqure Ip B.V. RNAi induced huntingtin gene suppression
JP2018500037A (ja) * 2014-12-31 2018-01-11 シンセティック ジェノミクス インコーポレーテッド 高効率なインビボゲノム編集のための組成物及び方法
IL297576B2 (en) * 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
US10457940B2 (en) * 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
CA3071769A1 (en) * 2017-07-31 2019-02-07 Reflection Biotechnologies Limited Cellular models of and therapies for ocular diseases
US11364309B2 (en) * 2017-11-10 2022-06-21 Norwegian University Of Science And Technology (Ntnu) Neuronal enhancers
AU2019382824A1 (en) * 2018-11-19 2021-06-03 Uniqure Ip B.V. Method and means to deliver miRNA to target cells
JP7730327B2 (ja) * 2019-12-20 2025-08-27 アスクバイオ インコーポレイテッド ハンチントン病を処置するための方法
GB202005732D0 (en) * 2020-04-20 2020-06-03 Synpromics Ltd Regulatory nucleic acid sequences
US20230365963A1 (en) * 2020-09-21 2023-11-16 Asklepios Biopharmaceutical, Inc. Methods for treating neurological disease

Similar Documents

Publication Publication Date Title
EP4206216B1 (en) Adeno-associated virus variant capsids and methods of use thereof
KR20240113624A (ko) Aav 캡시드 변이체 및 이의 용도
WO2023154693A1 (en) Aav capsid variants and uses thereof
JP2023542211A5 (cg-RX-API-DMAC7.html)
JP2022535749A5 (cg-RX-API-DMAC7.html)
US20250136981A1 (en) Compositions and methods comprising engineered short nuclear rna (snrna)
CN113557243A (zh) 用于神经变性疾病的基因疗法
KR20250102136A (ko) 중추 신경계에서의 유전자 발현을 위한 핵산 조절 요소 및 사용 방법
JP2023537980A5 (cg-RX-API-DMAC7.html)
KR20260016939A (ko) 아데노 부속 바이러스 캡시드 단백질, 이를 포함하는 아데노 부속 바이러스, 벡터 및 응용
US20260092291A1 (en) Novel dual helper plasmid
WO2025038430A1 (en) Aav capsid variants and uses thereof
JP2024515902A5 (cg-RX-API-DMAC7.html)
JP2023507741A5 (cg-RX-API-DMAC7.html)
CA3219287C (en) Dual helper plasmid
KR102814185B1 (ko) 라포라병을 예방 또는 치료하기 위한 재조합 아데노 연관 바이러스 및 이를 포함하는 약학적 조성물
US10105450B2 (en) Promoter compositions
US12305188B2 (en) Dual helper plasmid
EP4534097A1 (en) Composition for treating retinal or macular diseases
WO2025160429A1 (en) Artificial micrornas targeting snca
KR20260046127A (ko) 뇌 지향성 aav 변이체
KR20250080845A (ko) 라포라병을 예방 또는 치료하기 위한 재조합 아데노 연관 바이러스 및 이를 포함하는 약학적 조성물
TW202548014A (zh) 靶向亨丁頓舞蹈症之人工microrna
CN116670160A (zh) Dlx2载体
HK40121156A (en) Composition for treating retinal or macular diseases